Nitrofurantoin Dr. Reddy's Laboratories Uk (Nitrofurantoin)

Nitrofurantoin disrupts bacterial carbohydrate metabolism and cell‑wall synthesis by inhibiting key enzyme systems. This leads to accumulation of toxic metabolites and impairs DNA, RNA, and protein synthesis, resulting in bacteriostatic or bactericidal activity against common urinary pathogens.

The dosage of Nitrofurantoin Dr. Reddy's Laboratories Uk is determined by the prescribing clinician based on the patient’s condition, renal function, and local guidelines. Patients should follow the prescriber’s instructions and the product label.

Nitrofurantoin is classified as pregnancy category B, indicating it may be used when the potential benefit justifies the potential risk to the fetus. It is excreted in breast milk in small amounts; breastfeeding mothers should discuss risks and benefits with their healthcare provider.

To order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Compared with other agents such as trimethoprim‑sulfamethoxazole or fluoroquinolones, nitrofurantoin has a narrow spectrum focused on common urinary pathogens and a low propensity for promoting resistance. It is often preferred for uncomplicated infections but is unsuitable for patients with reduced renal function.

Store the product at ambient temperature, preferably below 25 °C. Keep it in the original packaging, protect from moisture and direct sunlight, and ensure the container is tightly closed to maintain stability.

Nitrofurantoin Dr. Reddy's Laboratories Uk is taken orally, usually with food or a full glass of water to improve absorption and reduce gastrointestinal irritation. The exact administration schedule should follow the prescriber’s directions.

Serious risks include pulmonary toxicity (interstitial pneumonitis or fibrosis), hepatotoxicity, hemolytic anemia in patients with G6PD deficiency, severe hypersensitivity reactions such as Stevens‑Johnson syndrome, and acute kidney injury. Patients should seek immediate medical attention if they experience respiratory difficulty, jaundice, severe rash, or sudden loss of kidney function.

Nitrofurantoin is contraindicated in patients with severe renal impairment (creatinine clearance <60 mL/min), known hypersensitivity to nitrofurantoin or other nitrofurans, and individuals with G6PD deficiency due to the risk of hemolysis. Caution is also advised for pregnant women near term and for patients with a history of pulmonary disease.